DK1795186T3 - Flupirtinomfattende lægemiddelformulering med en kontrolleret frisætning af det aktive middel - Google Patents

Flupirtinomfattende lægemiddelformulering med en kontrolleret frisætning af det aktive middel

Info

Publication number
DK1795186T3
DK1795186T3 DK06022985.3T DK06022985T DK1795186T3 DK 1795186 T3 DK1795186 T3 DK 1795186T3 DK 06022985 T DK06022985 T DK 06022985T DK 1795186 T3 DK1795186 T3 DK 1795186T3
Authority
DK
Denmark
Prior art keywords
flupirtine
active agent
controlled release
drug formulation
wide drug
Prior art date
Application number
DK06022985.3T
Other languages
English (en)
Other versions
DK1795186T4 (da
Inventor
Bernd Terhaag
Joachim Wolf
Asal Qadan
Barbara Faustmann
Original Assignee
Teva Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37908079&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1795186(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Gmbh filed Critical Teva Gmbh
Application granted granted Critical
Publication of DK1795186T3 publication Critical patent/DK1795186T3/da
Publication of DK1795186T4 publication Critical patent/DK1795186T4/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK06022985.3T 2005-11-08 2006-11-04 Flupirtinomfattende lægemiddelformulering med en kontrolleret frisætning af det aktive middel DK1795186T4 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102005054610A DE102005054610B4 (de) 2005-11-08 2005-11-08 Flupirtin enthaltende Arzneimittelzubereitung mit kontrollierter Wirkstofffreisetzung

Publications (2)

Publication Number Publication Date
DK1795186T3 true DK1795186T3 (da) 2014-01-27
DK1795186T4 DK1795186T4 (da) 2018-03-05

Family

ID=37908079

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06022985.3T DK1795186T4 (da) 2005-11-08 2006-11-04 Flupirtinomfattende lægemiddelformulering med en kontrolleret frisætning af det aktive middel

Country Status (8)

Country Link
EP (1) EP1795186B2 (da)
CY (1) CY1115709T1 (da)
DE (1) DE102005054610B4 (da)
DK (1) DK1795186T4 (da)
ES (1) ES2443468T5 (da)
PL (1) PL1795186T5 (da)
PT (1) PT1795186E (da)
RU (1) RU2352338C2 (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8222282B2 (en) 2008-06-09 2012-07-17 Teva Pharmaceuticals Usa, Inc. Sulfonate salts of 2-amino-3-carbethoxyamino-6-(4-fluoro-benzylamino)-pyridine
US8183267B2 (en) 2008-06-09 2012-05-22 Awd. Pharma Gmbh & Co. Kg Carboxylic acid salts of 2-amino-3-carbethoxyamino-6-(4-fluoro-benzylamino)-pyridine
DE102008051783A1 (de) * 2008-10-17 2010-04-22 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Valsartan enthaltende Tablette
AR087501A1 (es) 2011-08-09 2014-03-26 Hydra Biosciences Inc Compuestos inhibidores del canal ionico del potencial receptor transitorio trpa1
WO2013127539A2 (de) * 2012-03-02 2013-09-06 Meda Pharma Gmbh & Co. Kg Pharmazeutische formulierungen
US20140163048A1 (en) * 2012-08-09 2014-06-12 Cubist Pharmaceuticals, Inc. Compositions with increased stability for inhibiting transient receptor potential ion channel trpa1
US9394308B2 (en) 2013-01-18 2016-07-19 Merck Sharp & Dohme Corp. Inhibiting the transient receptor potential A1 ion channel
DE102013014417A1 (de) 2013-08-29 2015-03-05 Klinipharm Gmbh Schwammkollagen umfassende Zubereitungen mit definiertem in vivo-Freisetzungsprofil vor allem im Colon, deren Herstellung und Verwendung
CN109806233B (zh) * 2017-11-21 2022-05-20 北京泰德制药股份有限公司 一种含有氟吡汀或其药用盐的组合物及其制备方法
RU2680244C1 (ru) * 2017-12-28 2019-02-19 Общество С Ограниченной Ответственностью "Валента-Интеллект" Комбинации флупиртина и циклобензаприна для лечения болевых синдромов

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3416609A1 (de) * 1984-05-05 1985-11-07 Degussa Ag, 6000 Frankfurt 2-amino-3-ethoxycarbonylamino-6-(p-fluor-benzylamino)- pyridin-gluconat und pharmazeutische zubereitungen, die diese substanz enthalten
DE4319649A1 (de) * 1993-03-18 1994-09-22 Asta Medica Ag Feste Flupirtin enthaltende orale Darreichungsformen mit kontrollierter Wirkstoffabgabe
AUPN605795A0 (en) * 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
US7985422B2 (en) * 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
DE10328260A1 (de) * 2003-06-23 2005-01-27 Schmidt, K.-G., Dr. med. Flupirtine-Präparat
US20060240043A1 (en) * 2004-10-08 2006-10-26 Meyerson Laurence R Methods and compositions for treating migraine pain

Also Published As

Publication number Publication date
RU2006139127A (ru) 2008-05-20
EP1795186A2 (de) 2007-06-13
PT1795186E (pt) 2014-01-22
PL1795186T5 (pl) 2018-05-30
CY1115709T1 (el) 2017-01-25
ES2443468T3 (es) 2014-02-19
DK1795186T4 (da) 2018-03-05
ES2443468T5 (es) 2018-03-26
EP1795186B2 (de) 2017-12-06
EP1795186B1 (de) 2013-10-23
DE102005054610B4 (de) 2010-06-10
EP1795186A3 (de) 2007-10-24
DE102005054610A1 (de) 2007-07-12
RU2352338C2 (ru) 2009-04-20
PL1795186T3 (pl) 2014-05-30

Similar Documents

Publication Publication Date Title
DK1940351T3 (da) Formulering af småmolekylære lægemidler med langvarig frigørelse
CU20080052A7 (es) Formas de presentación farmacéutica sólidas de administración oral con liberación rápida de principio activo
DK2058020T3 (da) Indretning til indgivelse af lægemiddel
DK2073795T3 (da) Misbrugssikret lægemiddelformulation
DK1928438T3 (da) Anvendelse af ibudilast til behandling af stofafhængighed
BRPI0714539A2 (pt) "formas farmacêuticas"
BRPI0810696A2 (pt) Composto, composição farmacêutica, e, uso de um composto
IL188732A (en) Use of ibuprofen and famotidine in the preparation of medicaments
DK2054042T3 (da) Fremgangsmåder til fremstilling af biologisk aktive forbindelser i nanopartikelform
DK1940467T3 (da) Lægemiddelsammensætning med langvarig frigivelse
BRPI0815709A2 (pt) composro, composição farmacêutica, e, uso de um composto.
BRPI0818193A2 (pt) composto, sal farmacêuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto
BRPI0609802A2 (pt) composto, composição farmacêutica e uso de um composto
DK1886169T3 (da) Oftalmiske anordninger til opretholdt afgivelse aktive forbindelser
BRPI0821115A2 (pt) Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto
HRP20160866T1 (hr) Postupci primjene hipoglikemijskih sredstava
BRPI0915093A2 (pt) conjugados para a administração de compostos biologicamente ativos
BRPI0807078A2 (pt) Composto, e, formulação farmacêutica
DK2001297T3 (da) Aktivstofkombinationer insekticide egenskaber
BRPI0716698A2 (pt) Composto, composição farmacêutica e uso de um composto
BRPI0810019A2 (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0812942A2 (pt) Composto, composição farmacêutica e uso de um composto
BRPI0813587A2 (pt) Composto, uso do mesmo, e, composição farmacêutica
DK1954241T3 (da) Zonisamid-formulering med vedvarende frigivelse
IL201465A0 (en) Self-precipitating pharmaceutical formulations for the modified release of active principle